Luciano J. Costa, MD, PhD

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.